Approved Hospital Formulary
QR Code Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:

nirsevimab

nirsevimab
Brand names: Beyfortus
Form Strength
SOLUTION, INTRAMUSCULAR preservative-free 100 mg/mL (1 mL and 0.5 mL prefilled syringes)

VIEW MORE Monoclonal Antibodies
CLASS
081824

Additional Information:

Outpatient: Formulary (as recommended by ACIP)

Inpatient: Infants born in RSV season and whose mother did not receive the RSV vaccine > 14 days prior to delivery and meeting 1 of the following:

  • < 35 weeks gestational age
  • Hospitalized for the duration of the first week of life.
  • Any newborn or infant who has undergone a procedure that diminishes or eliminates maternal antibody status regardless of maternal vaccine status (i.e. cardiopulmonary bypass).

Please provide caregivers of eligible neonates with the Immunization Information Statement. (link: Immunization Information Sheet-RSV Preventive Antibody: What You Need to Know-September 25, 2023 (cdc.gov))


Last updated: Aug. 22, 2024







This site is intended for the staff of Legacy Health.
While others may view accessible pages, Legacy Health makes no warranty, express or implied,
as to the use of this information outside of Legacy Health.